Efficacy and Safety of the Proposed Biosimilar PERT-IJS Versus EU-Perjeta ® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Condition:   HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Interventions:   Biological: PERT-IJS plus trastuzumab, carboplatin and docetaxel;   Biological: Perjeta plus trastuzumab, carboplatin and docetaxel Sponsor:   Biocon Biologics UK Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials